Kura Oncology KURA Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Development Services For Monotherapy | $7.2M— | —— | —— | —— | —— | |
| Development Services In Combination With Other Therapies | $5.3M— | —— | —— | —— | —— | |
| License And Collaboration Revenue | $12.5M-11.4% | —— | —— | —— | $14.11M+4.7% | |
| Revenue Remaining Performance Obligation by Product | ||||||
| Commercialization Services | $275.7M— | $272.6M— | —— | —— | —— | |
| Development Services For Monotherapy | $27M— | $34.3M— | —— | —— | —— | |
| Development Services In Combination With Other Therapies | $161.7M— | $167M— | —— | —— | —— | |
| Research And Development Expense by Product | ||||||
| Darlifarnib | $6.57M+25.4% | $6.84M+17.9% | $8.49M+64.0% | $6.14M— | $5.24M— | |
| Discovery Stage Program | $1.4M-33.0% | $1.91M+14.1% | $1.74M-1.4% | $1.49M-13.0% | $2.09M+42.3% | |
| Ziftomenib | $36.88M+23.2% | $34.73M+28.6% | $40.32M+112% | $37.58M+99.4% | $29.95M+107% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Kura Oncology break its business down?
- Kura Oncology (KURA) reports revenue by product across 3 parts — Development Services For Monotherapy, Development Services In Combination With Other Therapies and License And Collaboration Revenue. Each is extracted from the segment footnotes and tracked over time.
- Where does Kura Oncology's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Kura Oncology's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
